

UC San Diego

UC San Diego Previously Published Works

Title

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

Permalink

<https://escholarship.org/uc/item/4j68r2bh>

Authors

Lacas, Benjamin
Carmel, Alexandra
Landais, Cécile
et al.

Publication Date

2021-03-01

DOI

10.1016/j.radonc.2021.01.013

Peer reviewed



HHS Public Access

Author manuscript

Radiother Oncol. Author manuscript; available in PMC 2021 August 25.

Published in final edited form as:

Radiother Oncol. 2021 March ; 156: 281–293. doi:10.1016/j.radonc.2021.01.013.

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

Benjamin Lacas^{a,b}, Alexandra Carmel^a, Cécile Landais^a, Stuart J. Wong^c, Lisa Licitra^d, Jeffrey S. Tobias^e, Barbara Burtness^f, Maria Grazia Ghi^g, Ezra E.W. Cohen^h, Cai Grauⁱ, Gregory Wolf^j, Ricardo Hitt^k, Renzo Corvò^l, Volker Budach^m, Shaleen Kumarⁿ, Sarbani Ghosh Laskar^o, Jean-Jacques Mazon^p, Lai-Ping Zhong^q, Werner Dobrowsky^r, Pirus Ghadjar^s, Carlo Fallai^t, Branko Zakotnik^u, Atul Sharma^v, René-Jean Bensadoun^w, Maria Grazia Ruo Redda^x, Séverine Racadot^y, George Fountzilas^z, David Brizel^{aa}, Paolo Rovea^{ab}, Athanassios Argiris^{ac}, Zoltán Takácsi-Nagy^{ad}, Ju-Whei Lee^{ae}, Catherine Fortpied^{af}, Jonathan Harris^{ag}, Jean Bourhis^{b,ah}, Anne Aupérin^{a,b}, Pierre Blanchard^{a,b,ai,*}, Jean-Pierre Pignon^{a,b} MACH-NC Collaborative Group

^aService de Biostatistique et d'Epidémiologie, Gustave Roussy, Oncostat U1018 INSERM, labeled Ligue Contre le Cancer, Université Paris-Saclay, Villejuif

^bGroupe d'Oncologie Radiothérapie Tête Et Cou, Tours, France

^cDepartment of Medicine, Medical College of Wisconsin, Milwaukee, USA

^dDepartment of Medical Oncology 3, Fondazione IRCCS-Istituto Nazionale dei Tumori, Milano and University of Milan, Italy

^eDepartment of Radiotherapy, University College London Hospital, UK

^fDepartment of Internal Medicine and Yale Cancer Center, Yale University, New Haven, USA

^gOncology Unit 2, Veneto Oncology Institute-IRCCS, Padua, Italy

^hUC San Diego, Moores Cancer Center, California, USA

ⁱDepartment of Experimental Clinical Oncology, Aarhus, Denmark

*Corresponding author at: Institut Gustave-Roussy, Département de Radiothérapie, 114 rue Edouard Vaillant, 94805 Villejuif cedex, France. pierre.blanchard@gustaveroussy.fr (P. Blanchard).

Contributors

PB, JB, and JPP with the help of the steering committee members designed and supervised the study.

PB, and JPP obtained funding.

PB, JB, JPP and BL searched and selected the trials. Steering committee members contributed to the identification and selection of the trials.

PB, BL and JPP collected and checked data with the help of the investigators who validated the re-analysis of their trials.

AA, BL, PB and JPP did the statistical analyses and wrote the draft, with revisions from the other investigators.

All authors contributed to the interpretation of the results during the investigator meeting and the revision of the manuscript. All investigators listed in Web-Appendix 1 received the manuscript for revision.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.radonc.2021.01.013>.

^jDepartment of Otolaryngology, University of Michigan, Ann Arbor, USA

^kServicio Oncologia Medica, Hospital Universitario Severo Ochoa, Madrid, Spain

^lDepartment of Radiation Oncology, Ospedale Policlinico San Martino and University of Genoa, Genoa, Italy

^mDepartment of Radiation Oncology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

ⁿDepartment of Radiotherapy, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow

^oDepartment of Radiation Oncology, Tata Memorial Hospital, Homi Bhabha National Institute Mumbai, India

^pDépartement de radiothérapie, hôpital Pitié-Salpêtrière, Paris, France

^qDepartment of Oral and Maxillofacial-Head and Neck Oncology, Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai, China

^rDept. Clinical Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom

^sDepartment of Radiation Oncology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany and SAKK Coordinating Center, Bern, Switzerland

^tDepartment of Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy

^uDepartment of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia

^vDepartments of Medical Oncology, Dr BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

^wDepartments of Radiation Oncology, Centre Antoine Lacassagne, Nice, France

^xDepartment of Radiation Oncology, Mauriziano Umberto I Hospital, University of Turin School of Medicine, Turin, Italy

^yDepartment of Radiation Oncology, Centre Léon Bérard, Lyon, France

^zAristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece

^{aa}Departments of Radiation Oncology, Duke University Medical Center, Durham, USA

^{ab}Radiation Oncology Unit, San Giovanni Antica Sede Hospital, Turin, Italy

^{ac}Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, USA

^{ad}Center of Radiotherapy, National Institute of Oncology, Department of Oncology, Semmelweis University, Budapest, Hungary

^{ae}Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, USA

^{af}EORTC Headquarters, Brussels, Belgium

^{ag}NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, USA

^{ah}Department of Radiotherapy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

^{ai}Department of Radiation Therapy, Gustave Roussy Cancer Campus, Université Paris-Sud, Université Paris-Saclay, Villejuif, France

Abstract

Background and purpose: The Meta-Analysis of Chemotherapy in squamous cell Head and Neck Cancer (MACH-NC) demonstrated that concomitant chemotherapy (CT) improved overall survival (OS) in patients without distant metastasis. We report the updated results.

Materials and methods: Published or unpublished randomized trials including patients with non-metastatic carcinoma randomized between 1965 and 2016 and comparing curative loco-regional treatment (LRT) to LRT + CT or adding another timing of CT to LRT + CT (main question), or comparing induction CT + radiotherapy to radiotherapy + concomitant (or alternating) CT (secondary question) were eligible. Individual patient data were collected and combined using a fixed-effect model. OS was the main endpoint.

Results: For the main question, 101 trials (18951 patients, median follow-up of 6.5 years) were analyzed. For both questions, there were 16 new (2767 patients) and 11 updated trials. Around 90% of the patients had stage III or IV disease. Interaction between treatment effect on OS and the timing of CT was significant ($p < 0.0001$), the benefit being limited to concomitant CT (HR: 0.83, 95% CI [0.79; 0.86]; 5(10)-year absolute benefit of 6.5% (3.6%)). Efficacy decreased as patients age increased ($p_{\text{trend}} = 0.03$). OS was not increased by the addition of induction (HR = 0.96 [0.90; 1.01]) or adjuvant CT (1.02 [0.92; 1.13]). Efficacy of induction CT decreased with poorer performance status ($p_{\text{trend}} = 0.03$). For the secondary question, eight trials (1214 patients) confirmed the superiority of concomitant CT on OS (HR = 0.84 [0.74; 0.95], $p = 0.005$).

Conclusion: The update of MACH-NC confirms the benefit and superiority of the addition of concomitant CT for non-metastatic head and neck cancer.

Keywords

Meta-analysis; Review; Individual Patient Data; Randomised Clinical Trials; Chemotherapy; Radiotherapy; Head and Neck Cancer

Concomitant chemoradiotherapy is the standard of care for locally advanced head and neck squamous cell carcinoma, either as definitive treatment or following surgery in case of pathological adverse features. The evidence supporting this statement comes from the multiple randomized trials, summarized in two individual patient data meta-analyses [1,2].

However, novel regimens, or combination of different chemotherapy timings such as taxane based triplet induction chemotherapy, have been tested prior to chemoradiotherapy or surgery [3], and an interaction between patient gender and chemotherapy effect was shown [4]. In addition, the importance of cytotoxic chemotherapy used in concomitance with radiotherapy has been recently reinforced by two trials that have shown the superiority of

concomitant cisplatin over concomitant cetuximab in the specific population of p16-positive oropharyngeal cancers [5,6].

The second update of the meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC) was performed to provide insights into long-term benefits of chemotherapy for non-metastatic locally advanced HNSCC.

Material and methods

The methods were pre-specified in a protocol (<https://www.gustaveroussy.fr/fr/meta-analyses-protocoles-dessais-ori>).

Selection criteria and search strategy

Trials were eligible if they had accrued previously untreated patients with HNSCC (oral cavity, oropharynx, hypopharynx and larynx) and compared curative loco-regional treatment with loco-regional treatment plus chemotherapy, the addition of another timing of chemotherapy to loco-regional treatment plus chemotherapy (main question), or compared induction chemotherapy and radiotherapy to the same concomitant (or alternating) chemoradiotherapy (secondary question). Trials were eligible if they completed accrual before December 31st, 2016 (Web-Appendix 2). To avoid publication bias, both published and unpublished trials were included. Electronic database searches (Medline, SCOPUS, CENTRAL, clinicaltrials.gov; Web-Appendix 3) were supplemented with hand searches of meeting abstracts (ASCO, ESTRO, ASTRO, ESMO, ECCO) and review articles. Experts and all trialists who took part in the meta-analysis were also asked to identify trials.

Data extraction and checking

Individual patient data (IPD) were requested for each eligible trial for all randomized patients. Data collected were patient and tumour characteristics, dates of randomization, failures and death, treatment group allocated, details about treatments received, and acute and late toxicities. Follow-up information was updated whenever possible. All data were checked with a standard procedure [7–9] which follows the recommendations of the Cochrane working group on meta-analysis using individual patient data (Web-Appendix 4). Each trial was analysed individually, and the resulting survival analyses as well as data description were sent to the trialists for review.

Outcomes

The primary endpoint was overall survival (OS), defined as the time from randomization until death from any cause. As in the previous update, secondary endpoints were event-free survival (EFS), loco-regional failure (LRF), distant failure (DF), cancer and non-cancer mortality [2]. A new endpoint, 120-day mortality, was added as proxy for deaths related to treatment [8]. EFS was defined as the time from randomization to first recurrence or progression (loco-regional or distant failure) or death from any cause. Events considered were loco-regional failures without distant failure for LRF; and distant failure, either alone or combined with loco-regional failures, for DF. Non-cancer mortality was defined as deaths without previous failure and resulting from known causes other than the treated head and

neck cancer. Cancer mortality included deaths from any cause with previous failure and deaths from the treated head and neck cancer. Deaths from unknown cause without previous failure were regarded as cancer mortality if they occurred within 5 years after randomization and as non-cancer mortality otherwise.

Secondary endpoints also included acute and late toxicities, and compliance; they have been collected but are not yet analysed. Those endpoints will be reported separately.

Statistical analysis

All analyses were done on an intention-to-treat basis. Median follow-ups were estimated with the reverse Kaplan-Meier method [10]. Analyses were stratified by trial. We calculated individual and overall pooled hazard ratios (HRs) with 95% CIs through a fixed-effects model using the method developed by Peto (*i.e.* log-rank expected number of events and variance) [11]. The Chi^2 heterogeneity test and I^2 statistic were used to investigate the overall heterogeneity between trials [12]. Methods used to estimate cancer and non-cancer mortality, to draw stratified curves and estimate 5-year and 10-year absolute differences were similar to the ones used in the previous meta-analyses: annual actuarial survival rates were computed on all patients and the HR at the corresponding time period was used to compute survival in each group [2,8,13,14]. A competing risk model was used for loco-regional and distant failure [15].

To study the robustness of the results several sensitivity analyses (*i.e.* analyses after exclusion of some trials) were realised (Web-Appendix 5). We performed subset analyses to study the interaction between treatment effect and trial level characteristics, using a test of heterogeneity among the different groups of trials. We estimated the interaction between treatment effect and patient subgroups (age, sex, performance status, smoking status, primary site, and overall stage) in a Cox model stratified by trial and adjusted on treatment effect, covariate effect (*e.g.* age), and treatment-covariate interaction (one-stage model method)[16]. Details about statistical methods including power estimation are available in Web-Appendix 5. Sensitivity, subset and subgroup analyses were pre-specified in the protocol except if mentioned otherwise in this publication.

Because of findings in our previous study [4], the interaction between sex and chemotherapy effect was studied in patients treated with or without surgery. Trials were excluded if it was not possible to separate patients treated with or without surgery.

All *p* values were two-sided. Analyses were done using SAS, version 9.4 and R software (“crrSC” package for competing risk analysis), version 3.6.3.

Results

The meta-analysis included 107 randomized trials (19805 patients). Sixteen new trials (2767 patients) [1,2,17–36] (Web-Fig. 1, Web-Appendix 6) and 2327 deaths (including death from updated previous trials) were added for this update. We were able to collect data from 725 of the 867 randomized patients who had been excluded from the original published analyses. Updated follow-up was obtained for 11 trials and the median follow-up of all trials was

6.6 years (interquartile range [IQR]: 4.3; 10.6). The description of the trials included and their references can be found in Web-Tables 1, 2, 3 and 4. Some trials with multiple strata (different loco-regional treatments or chemotherapies, three-arm trial or 2 by 2 design) were duplicated (Web-Table 5, Web-Appendix 7) or divided in two strata or more. Therefore, 138 comparisons and 21,863 patients were included in the meta-analysis.

The main question on the addition of chemotherapy included 130 comparisons (20,649 patients) and the secondary question on the comparison of induction and concomitant chemotherapy included eight comparisons (1214 patients) (SECOG II unpublished) [17,23,24,37–42].

Main question: addition of chemotherapy to locoregional treatment

Results will be presented by timing of chemotherapy. Patients are described in Web-Table 6. The distribution of the treatment comparison according to timing of chemotherapy, type of loco-regional treatment, type of chemotherapy and period of accrual is given in Web-Table 7.

Results are summarised in Table 1.

Effect of induction chemotherapy

Forty-five induction comparisons were available to evaluate the effect of induction chemotherapy (7054 patients, 4692 deaths, cause of death in Web-Table 8) with a median follow-up of 5.7 years (IQR: 4.2;7.6) [17–19,25–30,43–74].

The HR of death (Fig. 1A, Web-Fig. 2) was 0.96 [95% confidence interval (CI): 0.90; 1.01] ($p = 0.14$) in favour of induction chemotherapy with an absolute difference of 2.2% at 5 years (Fig. 2A). Similar results were observed for event-free survival (type of EFS events in Web-Table 9), with a HR of 0.96 [0.90; 1.02] ($p = 0.14$) and an absolute difference of 1.4% at 5 years (Web-Fig. 3A). No significant effect on 120-day mortality was observed (HR = 1.07 [0.89; 1.28], $p = 0.47$; Web-Fig. 4).

There was no significant variation of the effect on OS according to the type of induction chemotherapy (interaction test: $p = 0.22$): HR = 0.97 [0.82; 1.15] for taxane plus platin plus 5-FU (TPF), 0.90 [0.82; 0.99] for platin plus 5-FU (PF), 1.00 [0.92; 1.09] for other induction regimens, nor on EFS (test of interaction: $p = 0.20$). The exclusion (unplanned analysis) of the three comparisons with major early related to treatment mortality and/or without GCSF (two TPF comparisons (Budapest 2007, TTCC 2002 TPF) and one PF comparison (TTCC 2002 PF)) led to the following results: for OS, overall HR of 0.94 [0.89; 1.00] ($p = 0.06$) and HR of 0.83 [0.67; 1.02] ($p = 0.08$) for the TPF subset (interaction test $p = 0.08$); for EFS, overall HR of 0.95 [0.89; 1.01] ($p = 0.10$) and HR of 0.77 [0.64; 0.94]; $p = 0.02$) for the TPF (interaction test $p = 0.09$).

Excluding trials with more than one timing of chemotherapy, or confounded or less than 80 patients, or performed before 1980, or with a follow-up shorter than 5 years led to similar results for OS and EFS (Web-Table 10A). Analysis without arm duplication led to similar results (Web-appendix 7). In recent trials, it was possible to separate cancer and

non-cancer deaths (Web-Table 8). But data were not available in 11 comparisons out of 25. Effect of chemotherapy was not significant both for deaths related to head and neck cancer (HR = 0.97 [0.86; 1.10], $p = 0.67$ and an absolute difference of 0.7% at 5 years) and non-cancer deaths (0.84 [0.67; 1.05], $p = 0.12$) (Web-Fig. 5A). The effect addition of induction chemotherapy on LRF was not significant (sub-HR = 1.07 [95% CI = 0.99; 1.15], $p = 0.09$); Web-Figs. 6 and 8-A), when a significant decrease on DF was observed (0.76 [0.66; 0.88], $p = 0.0002$; Web-Figs. 7 and 9-A).

The effect of chemotherapy on OS and EFS did not differ significantly between the groups of trials according to chemotherapy modalities, year of start of accrual, or locoregional treatment (Web-Tables 11A, 12A, 12B, and 12C). There was no clear evidence of a differential effect of induction chemotherapy on overall or event-free survival according to age, sex, stage or tumour site (Web-Table 13A). There was a decreasing effect of chemotherapy with poorer performance status on OS (test for trend: $p = 0.03$) but not on EFS ($p = 0.07$) (Fig. 3A). With adjustment on sex and age, results were still significant for OS ($p = 0.02$) and borderline for EFS ($p = 0.05$).

Effect of concomitant chemotherapy

Seventy-one concomitant comparisons were available to evaluate the effect of concomitant chemotherapy (10,680 patients, 7944 deaths, cause of death in Web-Table 8) with a median follow-up of 9.2 years (IQR: 5.2; 12.9) [17,20–22,31–34,36,56,75–123]. The HR of death (Fig. 1A, Web-Fig. 10) was 0.83 [95% CI: 0.79; 0.86] ($p < 0.0001$) in favour of concomitant chemotherapy with an absolute benefit of 6.5% at 5 years and 3.6% at 10 years (Fig. 2B). The magnitude of the benefit was similar for the trials included in the initial meta-analysis and those included in the updates (test for interaction: $p = 0.77$), without significant heterogeneity in the most recent trials ($p = 0.30$).

Similar results were observed for event-free survival (Web-Table 9, Fig. 1B), with a HR of 0.80 [0.77; 0.84] ($p < 0.0001$) and an absolute benefit of 5.8% at 5 years and 3.1% at 10 years (Web-Fig. 3B). No significant effect on 120-day mortality was observed (HR = 1.07 [0.92; 1.24], $p = 0.37$; Web-Fig. 4).

Similar results were observed with the sensitivity analyses (Web-Table 10B). The benefit of chemotherapy was due to its effect on deaths related to head and neck cancer (HR = 0.79 [0.74; 0.84], $p < 0.0001$ and an absolute benefit of 9.8% at 5 years) (Web-Fig. 5B). There was no effect on non-cancer deaths (1.01 [0.89; 1.16], $p = 0.83$). Addition of concomitant chemotherapy showed a significant decrease of LRF (sub-HR = 0.71 [0.67; 0.75], $p < 0.0001$; Web-Figs. 6 and 8-B) with a non significant effect on DF (1.04 [0.92; 1.18], $p = 0.48$; Web-Figs. 7 and 9-B).

No significant variation of chemotherapy effect on OS and EFS was observed according to year of start of accrual or locoregional treatment (Web-Tables 11B, 12B, and 12C). For EFS, treatment effect varied significantly according to chemotherapy modality (test for interaction: $p = 0.01$) with the highest effect for polychemotherapy with platin salt (HR = 0.74 [0.67; 0.82]) and the lowest for monochemotherapy without platin salt (0.86 [0.80; 0.93]). For OS, interaction was borderline ($p = 0.06$) (Web-Table 12A). The only statistically

significant variation of treatment effect on survival according to patient characteristics (Web-Table 13B and Fig. 3B) was a decreasing effect of chemotherapy on OS with increasing age (test for trend: $p = 0.03$). Results were borderline for event-free survival ($p = 0.06$) (Fig. 3B). This effect could not be explained by an imbalance in the other covariates studied (data not shown). The cause of death was available only for the recent trials (1994–2010). As might be expected, the proportion of deaths not due to head and neck cancer increased with age from 18% in patients less than 50 to 37% in patients 70 and over (Web-Table 14). Adjusting on sex led to similar results for OS. Test for trend was also significant for EFS ($p = 0.04$).

Effect of adjuvant chemotherapy

Fourteen adjuvant comparisons were available to evaluate the effect of adjuvant chemotherapy (2915 patients, 1605 deaths, cause of death in Web-Table 8) with a median follow-up of 5.4 years (IQR: 3.6;8.7) [35,47,104,124–130]. The HR of death (Fig. 1A, Web-Fig. 11) was 1.02 [95% CI: 0.92; 1.13] ($p = 0.69$) with an absolute difference of -0.3% at 5 years (Fig. 2C). Similar results were observed for event-free survival (Web-Table 9, Fig. 1B), with a HR of 0.98 [0.88; 1.09] ($p = 0.72$) and an absolute difference of -0.6% at 5 years (Web-Fig. 3C). A deleterious effect on 120-day mortality was observed (HR = 1.89 [1.33; 2.68], $p = 0.0003$; Web-Fig. 4) without variation according to locoregional treatment modalities (data not shown).

Similar results were observed with the sensitivity analyses (Web-Table 10C). A significant decrease on LRF and DF was observed with the addition of adjuvant chemotherapy: sub-HR of 0.84 ([0.72; 1.00], $p = 0.04$); Web-Figs. 6 and 8-C) and of 0.77 ([0.62; 0.96], $p = 0.02$; Web-Figs. 7 and 9-C), respectively.

No significant variation of chemotherapy effect on OS and EFS was observed according to chemotherapy modalities or year of start of accrual (Web-Tables 11C, 12A, and 12B). A significant effect was observed on EFS, but not on OS for type of loco-regional treatment (interaction test $p = 0.005$) with HR of 0.77 [0.62; 0.96] in the comparisons using only surgery (Web-Table 12C).

Secondary question: concomitant versus induction chemotherapy

Eight comparisons used the same drugs in both arms, and compared the timing of their use relative to radiotherapy. They included 1214 patients (1007 deaths, Web-Table 15) with a median follow-up of 9.0 years (IQR: 7.0; 17.0) [17,23,24,37–42]. The analysis of DF was not performed because data were missing for half of the comparisons. All endpoints showed results in favour of the concomitant group: HR = 0.84 [95% CI: 0.74; 0.95] ($p = 0.005$) for OS (absolute benefit of 6.2% at 5 years, (Web-Figs. 12A, 13A), 0.85 [0.75; 0.96] ($p = 0.008$) for EFS (absolute benefit of 3.7% at 5 years) (Web-Figs. 12B, 13B), and 0.86 [0.76; 0.97] ($p = 0.01$) (absolute benefit of 5.8% at 5 years) for LRF. Results were not significantly different for the trials with or without platin.

Indirect comparison

Overall survival and event-free survival—The benefit of chemotherapy was significantly greater in the concomitant group than in the induction and adjuvant groups both for OS and EFS (interaction test: $p < 0.0001$ for both endpoints, Fig. 1).

120 days mortality—Out of 20,649 patients, 1313 (6%) died within 120-day after randomisation: 470 out of 7054 (7%), 716 out of 10,680 (7%) and 127 out of 2915 (4%) in the induction, concomitant, and adjuvant comparisons respectively. Overall, 120-day mortality increased with chemotherapy (HR = 1.13 [1.01; 1.26], $p = 0.03$, Web-Fig. 4) with a significant variation by timing (interaction test: $p = 0.01$). This deleterious effect was significant for adjuvant timing (HR = 1.89 [1.33; 2.68], $p = 0.0003$) but not for the two other timings. The overall heterogeneity observed was mainly explained by the significant interaction between timings and the heterogeneity within concomitant group (Web-Appendix 8).

Locoregional and distant failures—The analysis of LRF was based on 123 comparisons (18834 patients). The benefit of chemotherapy was significantly greater in the concomitant and adjuvant groups than in the induction group (interaction test: $p < 0.0001$; (Web-Figs. 6 and 8). The analysis of DF was based on 108 comparisons (16828 patients). The benefit of chemotherapy was significantly greater in the induction and adjuvant groups than in the concomitant group (interaction test: $p = 0.001$; (Web-Fig. 7 and 9).

Interaction between sex, surgery and treatment—Patients treated with surgery corresponded to 28 comparisons, 5503 patients and those treated without surgery 74 comparisons, 12,949 patients. These two populations had significantly different patient and tumour characteristics: differences were often small and, as expected, based of selection criteria for surgery (Web-Table 16). Among comparisons with surgery, a better effect of chemotherapy was observed in women compared to men: HR of 0.67 [0.54; 0.82] and 0.96 [0.89; 1.03] respectively (interaction test, $p = 0.001$) for OS with similar results for EFS. A gender effect was not significant for the comparisons without surgery: HR of 0.94 [0.85; 1.04] for women and 0.87 [0.83; 0.91] for men (interaction test, $p = 0.15$) for OS, with similar results for EFS (Web-Table 17).

Discussion

The present study provides the most comprehensive and robust analysis of the role of chemotherapy in combination with locoregional therapy for the treatment of non-metastatic HNSCC. It involved the individual data of 19,805 patients included in 107 randomized trials. Results were robust to multiple pre-specified sensitivity analyses. Given that the landscape of clinical trials has shifted from cytotoxic chemotherapy to targeted therapies and recently to immunotherapy, this analysis is likely to be the ultimate analysis on the topic. A set of major findings have been made and are discussed hereafter.

The analysis on induction chemotherapy demonstrated a survival benefit for the combination of platin and 5FU (PF) with a HR of 0.90 [95% CI: 0.82; 0.99] but failed to show a similar benefit for the triplet containing of taxane, platin and 5FU (TPF). This is surprising, as

the superiority of TPF over PF has been demonstrated in multiple trials and meta-analyses [3]. A few important facts about induction TPF should be noticed. First, some TPF trials were not included in the meta-analysis because they were confounded due to different concomitant treatments for the TPF and no induction arms [131,132]. Second, four out of the five trials included used chemoradiation as a comparator [18,19,25–28], whereas the vast majority of PF trials had RT alone as comparator. The bar was hence higher for TPF than for PF. As shown by our analyses, TPF may be associated with a high risk of treatment related death, as shown by an excess in early death in two trials that did not appropriately select patients or use G-CSF [18,19,25]. Excluding these trials led to a significant effect of this chemotherapy on EFS, but not on overall survival. Moreover, no effect of age could be demonstrated for induction chemotherapy but there was a significant decrease of the overall survival benefit with poorer performance status. Hence induction chemotherapy should be considered only for fit patients. To decrease TPF toxicity without changing efficacy, modified schedule of TPF has been proposed. But, data from randomized trial are currently limited and results mixed [133,134]. Better selection tools to identify patients who will benefit from TPF induction remain needed.

Concomitant chemoradiotherapy is the mainstay of treatment for locally advanced HNSCC whether as sole treatment or given as adjuvant after surgery, and this analysis confirms, with a much longer follow-up of 9.2 years, the OS benefit of 0.83 [0.79;0.86] with an absolute benefit of 6.5% and 3.6% at 5 and 10 years respectively. The decreasing effect of concomitant chemotherapy with increasing patient age is reinforced; thus, the use of concomitant chemotherapy should be carefully weighed after 70 years. As expected, concomitant chemotherapy mostly decreases locoregional failures, which are the first site of recurrence in HNSCC. Further, both direct and indirect comparisons demonstrated that concomitant chemotherapy yielded a greater survival advantage than induction. The subset analysis confirmed as well that platin-containing mono or polychemotherapy is the standard of care due to higher OS or EFS benefit. No comparison between three-weekly or weekly schedules of cisplatin could be performed as such trials were out of the scope of the meta-analysis.

Adjuvant chemotherapy after surgery or radiotherapy did not have significant effect on OS and EFS in spite of a significant beneficial effect on loco-regional and distant failure. Increase in 120-mortality, likely to be related to treatment may explain these results (Table 1). The adjuvant trials are old and used outdated systemic therapies. Their results are difficult to apply to current loco-regional treatment. However, in the light of the benefit of adjuvant chemotherapy after radiotherapy in nasopharyngeal cancer [135], adjuvant therapy might deserve further testing.

The major strengths of the meta-analysis are well-known. It followed a rigorous process, was overseen by a steering committee and involved the investigators of the included trials. For each trial, the IPD were collected and the data quality was checked and reanalyzed prior to inclusion in the final analysis. Unpublished trials were included. All analyses based on intent-to-treat principle were preplanned according to a protocol, unless explicitly specified. The high number of patients allowed rigorous assessment with adequate power association

for subgroups with treatment effect. Update allowed to increase the median follow-up of one-year from 5.6 to 6.6 years.

Limitations include the large time span of the randomized trials included, 1965–2012 during which time staging, treatments and supportive care have all greatly evolved. No interaction between period of accrual and overall survival or event-free survival was recorded and exclusion of the trials performed before 1980 led to similar results. Individual patient data were not available for 13 trials (1067 patients), but such trials appeared of lower quality, with fewer patients and with higher treatment effect than those included in IPD meta-analysis [136]. Three potentially eligible randomised trials (415 patients) were identified in 2019, but because of their design and size they are unexpected to have any impact on the conclusion of this work (Web-Table 18). To the best of our knowledge, no patient has been accrued in a trial eligible for this meta-analysis after 2012. For the secondary question, only few trials could be included and although they show the superiority of concomitant chemotherapy, a network meta-analysis would improve the estimation of relative treatment efficacy. No data on HPV or limited data on smoking status were available and given the timing of the trials and tumour subsites, most tumours are likely HPV-negative although this hypothesis cannot be confirmed. The superiority of concomitant cisplatin has been shown in HPV-positive oropharyngeal cancers compared to cetuximab and is in these studies of the same magnitude as in this analysis, with a 5-year benefit for cisplatin of 6.7% in RTOG 1016 [6]. No data on treatment compliance or toxicity have been presented here. Last, there are statistical limitations. The important number of endpoints analyzed raises the question of multiplicity of testing and the inflation of type I error. However, overall survival was the primary endpoint of the meta-analysis, most secondary endpoints and analyses were pre-specified, and there is consistency between main and secondary endpoints. Also the duplication of trial arms in case of multi-arms trials could bias the results, but analyses without duplication did not alter the results (Web-Appendix 7).

Practical implications of the meta-analysis are numerous. Firstly, they provide an accurate estimation of the effect of chemotherapy for each timing and regimen, which is essential for treatment personalization and patient counselling. In this respect, the interaction between patient performance status or age and the effect of induction or concomitant chemotherapy respectively are crucial, as could be the interaction between gender and the effect of chemotherapy in the postoperative setting [4]. This last interaction may be explained by a lower rate of comorbidities among women compared to men [4]. It needs to be confirmed in more recent trials. Predictive models to select treatments have been developed based on this dataset [137]. Secondly, these data are important to design future randomized trials as they can help define credible statistical hypotheses, potentially taking advantage of the multiple subgroup analyses that can help adapt calculation to the structure of the populations.

In conclusion, the present IPD meta-analysis clearly evaluates the benefit of induction and concomitant chemotherapy for the treatment of non-metastatic HNSCC, using data of all randomized trials published up to 2019. Given the many potential combinations of systemic therapy and radiotherapy, a network meta-analysis could be helpful to rank treatments and suggest large-scale trials. In the current context, these data are invaluable for the selection of regimens to be tested with the combination of immunotherapy.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We thank the trialists and the collaborative groups who agreed to share their data. The contents of this publication and methods used are solely the responsibility of the authors and do not necessarily represent the official views of the ECOG-ACRIN Cancer Research Group, and NRG Oncology. This research was funded by grants from Institut National du Cancer (Programme Hospitalier de Recherche Clinique) and Ligue Nationale Contre le Cancer.

Role of funding sources

The funding sources had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The submission of the paper for publication was decided by the MACH-NC collaborative group. AA, PB, BL, and J-PP had access to the raw data. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. All authors have seen and approved the final version and, after consultation with the collaborators, agreed to submit for publication.

References

- [1]. Pignon J-P, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. *Lancet*2000;355:949–55. [PubMed: 10768432]
- [2]. Pignon J-P, le Maître A, Maillard E, Bourhis J. MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. *Radiother Oncol*2009;92:4–14. 10.1016/j.radonc.2009.04.014. [PubMed: 19446902]
- [3]. Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Hernandez JJC, et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer Group. *J Clin Oncol*2013;31:2854–60. 10.1200/JCO.2012.47.7802. [PubMed: 23835714]
- [4]. Dauter E, Lacas B, Blanchard P, Le Q-T, Simon C, Wolf G, et al. Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. *Oral Oncol*2019;95:106–14. [PubMed: 31345376]
- [5]. Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. *Lancet*2019;393:51–60. 10.1016/S0140-6736(18)32752-1. [PubMed: 30449623]
- [6]. Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. *Lancet*2019;393:40–50. 10.1016/S0140-6736(18)32779-X. [PubMed: 30449625]
- [7]. Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. *Cochrane Working Group. Stat Med*1995;14:2057–79.
- [8]. Lacas B, Bourhis J, Overgaard J, Zhang Q, Grégoire V, Nankivell M, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. *Lancet Oncol*2017;18:1221–37. 10.1016/S1470-2045(17)30458-8. [PubMed: 28757375]
- [9]. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. *JAMA*2015;313:1657–65. 10.1001/jama.2015.3656. [PubMed: 25919529]
- [10]. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. *Control Clin Trials*1996;17:343–6. [PubMed: 8889347]

- [11]. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. *Progr Cardiovasc Dis*1985;27:335–71.
- [12]. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*2002;21:1539–58. 10.1002/sim.1186. [PubMed: 12111919]
- [13]. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. *Lancet*1992;339:71–85. [PubMed: 1345869]
- [14]. Early Breast Cancer Trialists' Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. *N Engl J Med*1995;333:1444–55. 10.1056/NEJM199511303332202. [PubMed: 7477144]
- [15]. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc*1999;94:496–509. 10.1080/01621459.1999.10474144.
- [16]. Fisher DJ, Copas AJ, Tierney JF, Parmar MKB. A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. *J Clin Epidemiol*2011;64:949–67. 10.1016/j.jclinepi.2010.11.016. [PubMed: 21411280]
- [17]. Kumar S, Datta NR, Nagar Y, Lal P, Singh S, Rastogi N, et al. A three-arm randomized trial comparing neo-adjuvant or concurrent weekly cisplatin to radiotherapy alone for locally advanced head and neck squamous cell cancer (HNSCC). *Eur J Cancer*2011;47(S1):547.
- [18]. Hitt R, Grau J, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, et al. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. *Ann Oncol*2014;25:216–25. 10.1093/annonc/mdt461. [PubMed: 24256848]
- [19]. Hitt R, Iglesias L, López-Pousa A, Berrocal-Jaime A, Grau JJ, García-Girón C, et al. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial. *Clin Transl Oncol*2020. 10.1007/s12094-020-02467-8.
- [20]. Argiris A, Karamouzis M, Johnson J, Heron D, Myers E, Eibling D, et al. Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer. *Laryngoscope*2008;118:444–9. 10.1097/MLG.0b013e31815b48f4. [PubMed: 18091334]
- [21]. Bensadoun R-J, Bénézy K, Dassonville O, Magné N, Poissonnet G, Ramaïoli, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). *Int J Radiat Oncol Biol Phys*2006;64:983–94. 10.1016/j.ijrobp.2005.09.041.
- [22]. Sharma A, Mohanti B, Thakar A, Bahadur S, Bhasker S. Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: A phase II randomized trial. *Ann Oncol*2010;21:2272–7. 10.1093/annonc/mdq219. [PubMed: 20427350]
- [23]. Lefebvre J, Rolland F, Tesselaar M, Bardet E, Leemans C, Geoffrois L, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. *J Natl Cancer Inst*2009;101:142–52. 10.1093/jnci/djn460. [PubMed: 19176454]
- [24]. Henriques De Figueiredo B, Fortpied C, Menis J, Lefebvre JL, Barzan L, de Raucourt D, et al. Long-term update of the 24954 EORTC phase III trial on larynx preservation. *Eur J Cancer*2016;65:109–12. 10.1016/j.ejca.2016.06.024. [PubMed: 27494036]
- [25]. Takacs-Nagy Z, Hitre E, Remenar E, Oberna F, Polgar C, Major T, et al. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study. *Strahlenther Onkol*2015;191:635–41. 10.1007/s00066-015-0829-z. [PubMed: 25782685]
- [26]. Cohen E, Karrison T, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. *J Clin Oncol*2014;32:2735–43. 10.1200/JCO.2013.54.6309. [PubMed: 25049329]

- [27]. Paccagnella A, Ghi M, Loreggian L, Buffoli A, Koussis H, Mione C, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: A phase II randomized study. *Ann Oncol*2010;21:1515–22. 10.1093/annonc/mdp573. [PubMed: 20032123]
- [28]. Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codeca C, et al. Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial. *Ann Oncol*2017;28:2206–12. 10.1093/annonc/mdx299. [PubMed: 28911070]
- [29]. Zhong L-P, Zhang C-P, Ren G-X, Guo W, William WNJ, Hong C, et al. Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma. *Oncotarget*2015;6:18707–14. [PubMed: 26124084]
- [30]. Zhong L-P, Zhang C-P, Ren G-X, Guo W, William WJ Jr, Sun J, et al. Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. *J Clin Oncol*2013;31:744–51. 10.1200/JCO.2012.43.8820. [PubMed: 23129742]
- [31]. Ruo Redda MG, Ragona R, Ricardi U, Beltramo G, Rampino M, Gabriele P, et al. Radiotherapy alone or with concomitant daily low-dose carboplatin in locally advanced, unresectable head and neck cancer: definitive results of a phase III study with a follow-up period of up to ten years. *Tumori*2010;96:246–53. [PubMed: 20572581]
- [32]. Racadot S, Mercier M, Dussart S, Dessard-Diana B, Bensadoun R-J, Martin M, et al. Randomized clinical trial of post-operative radiotherapy versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement. *Radiother Oncol*2008;87:164–72. 10.1016/j.radonc.2007.12.021. [PubMed: 18222010]
- [33]. Boidi Trotti A, Rovea P, Gabriele AM, Tseroni V, Fracchia F, Raiteri M, et al. The use of cisplatin as radiosensitizing agent in advanced tumors of the head and neck. Randomized study. *La Radiol Med*1991;82:504–7.
- [34]. Haddad E, Mazon JJ, Martin M, Vergnes L, Brun B, Piedbois P, et al. Comparison of concomitant radiotherapy and chemotherapy with radiotherapy alone in advanced cancers of the head and neck: results of a randomized trial. *Bull Cancer Radiother*1996;83:97–103. [PubMed: 8688226]
- [35]. Ervin TJ, Clark JR, Weichselbaum RR, Fallon BG, Miller D, Fabian RL, et al. An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. *J Clin Oncol*1987;5:10–20. 10.1200/JCO.1987.5.1.10. [PubMed: 2433406]
- [36]. Ghosh-Laskar S, Kalyani N, Gupta T, Budrukkar A, Murthy V, Sengar M, et al. Conventional radiotherapy versus concurrent chemoradiotherapy versus accelerated radiotherapy in locoregionally advanced carcinoma of head and neck: Results of a prospective randomized trial. *Head Neck*2016;38:202–7. 10.1002/hed.23865. [PubMed: 25224814]
- [37]. Adelstein D, Sharan V, Earle A, Shah A, Vlastou C, Haria C, et al. Simultaneous versus sequential combined technique therapy for squamous cell head and neck cancer. *Cancer*1990;65:1685–91. [PubMed: 2317751]
- [38]. Adelstein D, Sharan V, Earle A, Shah A, Vlastou C, Haria C, et al. Long-term follow-up of a prospective randomized trial comparing simultaneous and sequential chemoradiotherapy for squamous cell head and neck cancer. *Adjuvant therapy of cancer VII, Philadelphia, PA: Lippincott Company; 1993, p. 82–91.*
- [39]. A randomized trial of combined multidrug chemotherapy and radiotherapy in advanced squamous cell carcinoma of the head and neck. An interim report from the SECOG participants. *Eur J Surg Oncol*1986;12:289–95. [PubMed: 2428668]
- [40]. Buffoli A, Morrica B, Frata P, La Face B. Chemo-radiotherapy in advanced head and neck tumors. Personal experience. *La Radiologia medica*1992;83:636–40. [PubMed: 1378641]
- [41]. Taylor SG, Murthy AK, Vannetzel J-M, Colin P, Dray M, Caldarelli DD, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. *J Clin Oncol*1994;12:385–95. [PubMed: 8113846]

- [42]. Merlano M, Corvo R, Margarino G, Benasso M, Rosso R, Sertoli MR, et al. Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial. *Cancer* 1991;67:915–21. [PubMed: 1703916]
- [43]. Richard JM, Sancho H, Lepintre Y, Rodary J, Pierquin B. Intra-arterial methotrexate chemotherapy and telecobalt therapy in cancer of the oral cavity and oropharynx. *Cancer* 1974;34:491–6. 10.1002/1097-0142(197409)34:3**491::AID-CNCR2820340303**3.0.CO;2-G. [PubMed: 4852531]
- [44]. Fazekas J, Sommer C, Kramer S. Adjuvant intravenous methotrexate or definitive radiotherapy alone for advanced squamous cancers of the oral cavity, oropharynx, supraglottic larynx or hypopharynx. Concluding report of an RTOG randomized trial on 638 patients. *Int J Radiat Oncol Biol Phys* 1980;6:533–41. 10.1016/0360-3016(80)90379-X. [PubMed: 7410127]
- [45]. Jortay A, Demard F, Dalesio O, Blanchet C, Desautly A, Gehanno C, et al. A randomized EORTC study on the effect of preoperative polychemotherapy in pyriform sinus carcinoma treated by pharyngolaryngectomy and irradiation. Results from 5 to 10 years. *Acta Chirurgica Belgica* 1990;90:115–22. [PubMed: 1695801]
- [46]. Pearlman NW, Johnson FB, Braun TJ, Kennaugh RC, Spofford BF, Borlase BC, et al. A prospective study of preoperative chemotherapy and split-course irradiation for locally advanced or recurrent oral/pharyngeal squamous carcinoma. *Am J Clin Oncol* 1985;8:490–6. 10.1097/00000421-198512000-00008. [PubMed: 2417476]
- [47]. Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the Head and Neck Contracts Program. *Cancer* 1987;60:301–11. 10.1002/1097-0142(19870801)60:3**301::aid-cnrcr2820600306**3.0.co;2-v. [PubMed: 2885080]
- [48]. Richard J, Kramar A, Molinari R, Lefebvre J, Blanchet F, Jortay A, et al. Randomised EORTC Head and Neck Cooperative Group trial of preoperative intra-arterial chemotherapy in oral cavity and oropharynx carcinoma. *Eur J Cancer* 1991;27:821–7. 10.1016/0277-5379(91)90125-W. [PubMed: 1718348]
- [49]. Holoye PY, Grossman TW, Toohill RJ, Kun LE, Byhardt RW, Duncavage JA, et al. Randomized study of adjuvant chemotherapy for head and neck cancer. *Otolaryngol-Head Neck Surg* 1985;93:712–7. [PubMed: 2418400]
- [50]. Kun LE, Toohill RJ, Holoye PY, Duncavage JA, Byhardt RW, Ritch PS, et al. A randomized study of adjuvant chemotherapy for cancer of the upper aerodigestive tract. *Int J Radiat Oncol Biol Phys* 1986;12:173–8. 10.1016/0360-3016(86)90090-8. [PubMed: 2419292]
- [51]. Schuller DE, Metc B, Stein DW, Mattox D, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. *Laryngoscope* 1988;98:1205–11. 10.1288/00005537-198811000-00011. [PubMed: 3054373]
- [52]. Szpirglas H, Nizri D, Marneur M, Lacoste J, Benslama L. Neoadjuvant chemotherapy. A randomized trial before radiotherapy in oral and oropharyngeal carcinomas: end results. Proceedings of the 2nd international head and neck oncology research conference. Ghedini Ed, Berkeley: Kugler Publications; 1988, p. 261–4.
- [53]. Carugati A, Pradier R, De La Torre A. Combination chemotherapy pre-radical treatment for head and neck squamous cell carcinoma. *Proc Am Soc Clin Oncol* 1988;7:152.
- [54]. Mazon J, Martin M, Brun B, Grimard L, Lelièvre G, Vergnes L, et al. Induction chemotherapy in head and neck cancer: Results of a phase III trial. *Head Neck* 1992;14:85–91. 10.1002/hed.2880140202. [PubMed: 1376306]
- [55]. Brunin F, Rodriguez J, Jaulerry C, Jouve M, Pontvert D, Point D, et al. Induction chemotherapy in advanced head and neck cancer. Preliminary results of a randomized study. *Acta Oncologica* 1989;28:61–5. 10.3109/02841868909111183. [PubMed: 2650723]
- [56]. Salvajoli J, Morioka H, Trippe N, Kowalski L. A randomized trial of neoadjuvant vs concomitant chemotherapy vs radiotherapy alone in the treatment of stage IV head and neck squamous cell carcinoma. *Eur Arch Oto-Rhino-Laryngol* 1992;249:211–5.
- [57]. Jaulerry C, Rodriguez J, Brunin F, Jouve M, Mosseri V, Point D, et al. Induction chemotherapy in advanced head and neck tumors: Results of two randomized trials. *Int J Radiat Oncol Biol Phys* 1992;23:483–9. 10.1016/0360-3016(92)90002-Y. [PubMed: 1612948]

- [58]. Maipang T, Maipang M, Geater A, Panjapiyakul C, Watanaarepornchai S, Punperk S. Combination chemotherapy as induction therapy for advanced resectable head and neck cancer. *J Surg Oncol*1995;59:80–5. 10.1002/jso.2930590203. [PubMed: 7539873]
- [59]. Toohill R, Anderson T, Byhardt R, Cox J, Duncavage J, Grossman T, et al. Cisplatin and fluorouracil as neoadjuvant therapy in head and neck cancer. *Arch Otolaryngol Head Neck Surg*1987;113:758–61. [PubMed: 3580158]
- [60]. Toohill R, Duncavage J, Thomas M, Wilson F, Anderson T, et al. The effects of delay in standard treatment due to induction chemotherapy in two randomized prospective studies. *Laryngoscope*1987;97:407–12. 10.1288/00005537-198704000-00002. [PubMed: 3550340]
- [61]. Lewin F, Damber L, Jonsson H, Andersson T, Berthelsen A, Björklund A, et al. Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: A randomized phase III study. *Radiother Oncol*1997;43:23–8. 10.1016/S0167-8140(97)01922-1. [PubMed: 9165133]
- [62]. Martin M, Hazan A, Vergnes L, Peytral C, Mazon JJ, Sénéchaut JP, et al. Randomized study of 5 fluorouracil and cis platin as neoadjuvant therapy in head and neck cancer: A preliminary report. *Int J Radiat Oncol Biol Phys*1990;19:973–5. 10.1016/0360-3016(90)90021-B. [PubMed: 2211266]
- [63]. Martin M, Vergnes L, Lelièvre G, Michel-Langlet P, Peytral C, Mazon J, et al. A randomized study of CDDP and 5-FU as neoadjuvant chemotherapy in head and neck cancer: an interim analysis. In: Banzet P, Holland J, Khayat D, Weil M, editors. *Cancer treatment: an update*. Springer-V, Paris: 1994, p. 214–8.
- [64]. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. *J Natl Cancer Inst*1994;86:265–72. 10.1093/jnci/86.4.265. [PubMed: 8158680]
- [65]. Zorat PL, Paccagnella A, Cavaniglia G, Loreggian L, Gava A, Mione CA, et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. *J Natl Cancer Inst*2004;96:1714–7. 10.1093/jnci/djh306. [PubMed: 15547184]
- [66]. Domenge C, Hill C, Lefebvre J, De Raucourt D, Rhein B, Wibault P, et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. *Br J Cancer*2000;83:1594–8. 10.1054/bjoc.2000.1512. [PubMed: 11189100]
- [67]. Dalley D, Beller E, Aroney R, Dewar J, Page J, Philip R, et al. The value of chemotherapy (CT) prior to definitive local therapy (DTL) in patients with locally advanced squamous cell carcinoma (SCC) of the head and neck (HN). *Proc Am Soc Clin Oncol*1995;14:297.
- [68]. Tejedor M, Murias A, Soria P, Aguiar J, Salinas J, Hernandez MA, et al. Induction chemotherapy with carboplatin and ftorafur in advanced head and neck cancer. A randomized study. *Am J Clin Oncol*1992;15:417–21. [PubMed: 1524042]
- [69]. Gedouin D, Desprez P, Perron JJ, Fleury F, Leclech G, Miglianico L, et al. Cancers de la base de langue et de l'hypopharynx: résultats d'un essai multicentrique randomisé de chimiothérapie avant traitement locoregional. *Bull Cancer/Radiother*1996;83:104–7. 10.1016/0924-4212(96)85320-5.
- [70]. Di Blasio B, Barbieri W, Bozzetti A, Iotti C, Di Sarra S, Cocconi G. A prospective randomized trial in resectable head and neck carcinoma: loco-regional treatment with and without neoadjuvant chemotherapy. *Proc Am Soc Clin Oncol*1994;13:279.
- [71]. Gehanno P, Depondt J, Peynegre R, Peytral C, Martin M, Baillet F, et al. Neoadjuvant combination of carboplatin and 5-FU in head and neck cancer: A randomized study. *Ann Oncol*1992;3:43–6. [PubMed: 1390316]
- [72]. Depondt J, Gehanno P, Martin M, Lelievre G, Guerrier B, Peytrale C, et al. Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer. *Oncology*1993;50:23–7. 10.1159/000227257. [PubMed: 8233298]
- [73]. Volling P, Schroder M, Muller RP, Ebeling O, Quirin R, Stennert E. Induction chemotherapy in primary resectable head and neck tumors: A prospective randomized trial. *Int J Oncol*1994;4:909–14. 10.3892/ijo.4.4.909. [PubMed: 21567001]

- [74]. Hasegawa Y, Matsuura H, Fukushima M, Kano M, Shimozato K. Potential suppression of distant and node metastasis by neoadjuvant chemotherapy in advanced head and neck cancer: result of a randomized trial. *Proc Am Soc Clin Oncol*1996;15:318.
- [75]. Hussey DH, Abrams JP. Combined therapy in advanced head and neck cancer: hydroxyurea and radiotherapy. *Progr Clin Cancer*1975;6:79–86.
- [76]. Eschwege F, Sancho-Garnier H, Gerard JP, Madelain M, DeSaulty A, Jortay A, et al. Ten-year results of randomized trial comparing radiotherapy and concomitant bleomycin to radiotherapy alone in epidermoid carcinomas of the oropharynx: experience of the European Organization for Research and Treatment of Cancer. *NCI Monographs*1988;6:275–8.
- [77]. Parvinen L-M, Parvinen M, Nordman E, Kortekangas AE. Combined bleomycin treatment and radiation therapy in squamous cell carcinoma of the head and neck region. *Acta Radiol Oncol*1985;24:487–9. 10.3109/02841868509134421. [PubMed: 2420153]
- [78]. Vermund H, Kaalhus O, Winther F, Trausjø J, Thorud E, Harang R. Bleomycin and radiation therapy in squamous cell carcinoma of the upper aero-digestive tract: A phase III clinical trial. *Int J Radiat Oncol Biol Phys*1985;11:1877–86. 10.1016/0360-3016(85)90267-6. [PubMed: 2414253]
- [79]. Sanchiz F, Milla A, Torner J, Bonet F, Artola N, Carreno L, et al. Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. *Int J Radiat Oncol Biol Phys*1990;19:1347–50. [PubMed: 2262356]
- [80]. Gupta NK, Pointon RC, Wilkinson PM. A randomised clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. *Clin Radiol*1987;38:575–81. [PubMed: 3121233]
- [81]. Gupta NK, Swindell R. Concomitant methotrexate and radiotherapy in advanced head and neck cancer: 15-year follow-up of a randomized clinical trial. *Clin Oncol*2001;13:339–44. 10.1053/clon.2001.9286.
- [82]. Haselow R, Warshaw M, Oken M, Adams G, Aughey J, Cooper J, et al. Radiation alone versus radiation with weekly low dose cisplatin in unresectable cancer of the head and neck. *Head and Neck Cancer. Vol II*, Philadelphia, PA: BC Decker; 1990, p. 279–81.
- [83]. Quon H, Leong T, Haselow R, Leipzig B, Cooper J, Forastiere A. Phase III study of radiation therapy with or without cis-platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: an intergroup trial of the Eastern Cooperative Oncology Group (E2382). *Int J Radiat Oncol Biol Phys*2011;81:719–25. 10.1016/j.ijrobp.2010.06.038. [PubMed: 20888709]
- [84]. Browman GP, Cripps C, Hodson DI, Eapen L, Sathya J, Levine MN. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. *J Clin Oncol*1994;12:2648–53. 10.1200/jco.1994.12.12.2648. [PubMed: 7989940]
- [85]. Jeremic B, Shibamoto Y, Stanisavljevic B, Milojevic L, Milicic B, Nikolic N. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: A prospective randomized trial. *Radiother Oncol*1997;43:29–37. 10.1016/S0167-8140(97)00048-0. [PubMed: 9165134]
- [86]. Wendt TG, Grabenbauer GG, Rödel CM, Thiel H-J, Aydin H, Rohloff R, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter study. *J Clin Oncol*1998;16:1318–24. [PubMed: 9552032]
- [87]. Smid L, Lesnicar H, Zakotnik B, Soba E, Budihna M, Furlan L, et al. Radiotherapy, combined with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer—preliminary report. *Int J Radiat Oncol Biol Phys*1995;32:769–75. [PubMed: 7540606]
- [88]. Shanta V, Krishnamurthi S. Combined bleomycin and radiotherapy in oral cancer. *Clin Radiol*1980;31:617–20. [PubMed: 6162599]
- [89]. Kapstad B, Bang G, Rennæs S, Dahler A. Combined preoperative treatment with cobalt and bleomycin in patients with head and neck carcinoma—a controlled clinical study. *Int J Radiat Oncol Biol Phys*1978;4:85–9. [PubMed: 75878]
- [90]. Morita K. Clinical significance of radiation therapy combined with chemotherapy. *Strahlentherapie*1980;156:228–33. [PubMed: 6154345]

- [91]. Bezwoda WR, de Moor NG, Derman DP. Treatment of advanced head and neck cancer by means of radiation therapy plus chemotherapy—a randomised trial. *Med Pediatr Oncol*1979;6:353–8. 10.1002/mpo.2950060412. [PubMed: 384188]
- [92]. Nissenbaum M, Browde S, Bezwoda WR, de Moor NG, Derman DP. Treatment of advanced head and neck cancer: multiple daily dose fractionated radiation therapy and sequential multimodal treatment approach. *Med Pediatr Oncol*1984;12:204–8. 10.1002/mpo.2950120312. [PubMed: 6203024]
- [93]. Weissberg JB, Son YH, Papac RJ, Sasaki C, Fischer DB, Lawrence R, et al. Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. *Int J Radiat Oncol Biol Phys*1989;17:3–9. [PubMed: 2501243]
- [94]. Keane T, Cummings B, O’Sullivan B, Payne D, Rawlinson E, Mackenzie R, et al. A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin C and 5 fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma. *Int J Radiat Oncol Biol Phys*1993;25:613–8. 10.1016/0360-3016(93)90006-H. [PubMed: 8454478]
- [95]. Bachaud J-M, Cohen-Jonathan E, Alzieu C, David J-M, Serrano E, DalySchweitzer N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: Final report of a randomized trial. *Int J Radiat Oncol Biol Phys*1996;36:999–1004. 10.1016/S0360-3016(96)00430-0. [PubMed: 8985019]
- [96]. Weissler MC, Melin S, Sailer SL, Qaqish BF, Rosenman JG, Pillsbury HC 3rd. Simultaneous chemoradiation in the treatment of advanced head and neck cancer. *Arch Otolaryng Head Neck Surg*1992;118:806–10. [PubMed: 1642831]
- [97]. Haffty BG, Son YH, Sasaki CT, Papac R, Fischer D, Rockwell S, et al. Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: Results from two randomized clinical trials. *Int J Radiat Oncol Biol Phys*1993;27:241–50. 10.1016/0360-3016(93)90234-M. [PubMed: 7691784]
- [98]. Merlano M, Vitale V, Rosso R, Benasso M, Corvo R, Cavallari M, et al. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. *N Engl J Med*1992;327:1115–21. [PubMed: 1302472]
- [99]. Merlano M, Benasso M, Corvò R, Rosso R, Vitale V, Blengio F, et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. *J Natl Cancer Inst*1996;88:583–9. 10.1093/jnci/88.9.583. [PubMed: 8609658]
- [100]. Kumar S, Datta NR, Ahuja RC, Mali HR, Agarwal GN, Ayyagari S. Feasibility of non-cisplatin-based induction chemotherapy and concurrent chemoradiotherapy in advanced head and neck cancer. *Acta Oncol (Stockholm, Sweden)*1996;35:721–5. 10.3109/02841869609084005.
- [101]. Adelstein DJ, Lavertu P, Saxton JP, Secic M, Wood BG, Wanamaker JR, et al. Mature results of a Phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with Stage III and IV squamous cell carcinoma of the head and neck. *Cancer*2000;88:876–83. 10.1002/(SICI)1097-0142(20000215)88:4<876::AID-CNCR19**3.0.CO;2-Y. [PubMed: 10679658]
- [102]. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. *N Engl J Med*1998;338:1798–804. 10.1056/NEJM199806183382503. [PubMed: 9632446]
- [103]. Dobrowsky W, Naudé J. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. *Radiother Oncol*2000;57:119–24. 10.1016/S0167-8140(00)00233-4. [PubMed: 11054514]
- [104]. Tobias JS, Monson K, Gupta N, Macdougall H, Glaholm J, Hutchison I, et al. Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. *Lancet Oncol*2010;11:66–74. 10.1016/S1470-2045(09)70306-7. [PubMed: 19875337]
- [105]. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. *J Clin Oncol*2000;18:1458–64. 10.1200/JCO.2000.18.7.1458. [PubMed: 10735893]

- [106]. Giglio R, Mickiewicz E, Pradier R, Roth B, Gatica G, Califano L, et al.No recurrence beyond the second year of follow-up in inoperable stage III and IV squamous cell carcinoma of the head and neck patients (IOHN). Final report of a randomized trial of alternating chemotherapy (CT) + hyperfractionated radiotherapy (RT) vs RT. *Proc Am Soc Clin Oncol*1999;15:317.
- [107]. Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, et al.An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. *J Clin Oncol*2003;21:92–8. 10.1200/JCO.2003.01.008. [PubMed: 12506176]
- [108]. Forastiere AA, Goepfert H, Maor M, Pajak T, Weber R, Morrison W, et al.Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. *N Engl J Med*2003;349:2091–8. 10.1056/NEJMoa031317. [PubMed: 14645636]
- [109]. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al.Long-term results of RTOG 91–11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. *J Clin Oncol*2013;31:845–52. 10.1200/JCO.2012.43.6097. [PubMed: 23182993]
- [110]. Olmi P, Crispino S, Fallai C, Torri V, Rossi F, Bolner A, et al.Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy—a multicenter randomized trial. *Int J Radiat Oncol Biol Phys*2003;55:78–92. [PubMed: 12504039]
- [111]. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al.Final results of the 94–01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. *J Clin Oncol*2004;22:69–76. 10.1200/JCO.2004.08.021. [PubMed: 14657228]
- [112]. Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, et al.Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer. *J Clin Oncol*2005;23:1125–35. 10.1200/JCO.2005.07.010. [PubMed: 15718308]
- [113]. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre J-L, Greiner RH, et al.Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. *N Engl J Med*2004;350:1945–52. 10.1056/NEJMoa032641. [PubMed: 15128894]
- [114]. Huguenin P, Beer KT, Allal A, Ruffibach K, Friedli C, Davis JB, et al.Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. *J Clin Oncol*2004;22:4665–73. 10.1200/JCO.2004.12.193. [PubMed: 15534360]
- [115]. Ghadjar P, Simcock M, Studer G, Allal AS, Ozsahin M, Bernier J, et al.Concomitant cisplatin and hyperfractionated radiotherapy in locally advanced head and neck cancer: 10-year follow-up of a randomized phase III trial (SAKK 10/94). *Int J Radiat Oncol Biol Phys*2012;82:524–31. [PubMed: 21300466]
- [116]. Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, et al.Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - Results of a multicentric randomized German trial in advanced head-and-neck cancer. *Int J Radiat Oncol Biol Phys*2001;50:1161–71. 10.1016/S0360-3016(01)01544-9. [PubMed: 11483325]
- [117]. Fountzilas G, Ciuleanu E, Dafni U, Plataniotis G, Kalogera-Fountzila A, Samantas E, et al.Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer: A Hellenic Cooperative Oncology Group Phase III Study. *Med Oncol*2004;21:95–107. [PubMed: 15299181]
- [118]. Cooper J, Pajak T, Forastiere A, Jacobs J, Campbell B, Saxman S, et al.Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. *N Engl J Med*2004;350:1937–44. 10.1056/NEJMoa032646. [PubMed: 15128893]
- [119]. Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, et al.Long-term follow-up of the RTOG 9501/intergroup phase III trial: Postoperative concurrent radiation therapy and

- chemotherapy in high-risk squamous cell carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys*2012;84:1198–205. 10.1016/j.ijrobp.2012.05.008. [PubMed: 22749632]
- [120]. Grau C, Prakash Agarwal J, Jabeen K, Rab Khan A, Abeyakoon S, Hadjieva T, et al. Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial. *Radiother Oncol*2003;67:17–26. 10.1016/S0167-8140(03)00020-3. [PubMed: 12758236]
- [121]. Bourhis J, Lapeyre M, Tortochaux J, Lusinchi A, Etessami A, Ducourtieux M, et al. Accelerated radiotherapy and concomitant high dose chemotherapy in non resectable stage IV locally advanced HNSCC: results of a GORTEC randomized trial. *Radiother Oncol*2011;100:56–61. 10.1016/j.radonc.2011.07.006. [PubMed: 21831465]
- [122]. Lartigau E, Giralt J, Glassman P, Lawton A, von Roemeling R. A phase III double-blind randomized placebo controlled study of porfiromycin and radiation therapy in patients with head and neck cancer. *Int J Radiat Oncol Biol Phys*2002;54(S2):74. 10.1016/S0360-3016(02)03184-X.
- [123]. Zakotnik B, Budihna M, Smid L, Soba E, Strojjan P, Fajdiga I, et al. Patterns of failure in patients with locally advanced head and neck cancer treated postoperatively with irradiation or concomitant irradiation with Mitomycin C and Bleomycin. *Int J Radiat Oncol Biol Phys*2007;67:685–90. 10.1016/j.ijrobp.2006.09.018. [PubMed: 17197122]
- [124]. Szpirglas H, Chastang CI, Bertrand JCh. Adjuvant treatment of tongue and floor of the mouth cancers. In: Bonadonna G, Mathé G, Salmon S, editors. *Adjuvant therapies and markers of post-surgical minimal residual disease II. Adjuvant therapies of the various primary tumors*, Berlin: Springer-Verlag; 1979, p. 309–17. 10.1007/978-3-642-81332-0_47.
- [125]. Domenge C, Marandas P, Vignoud J, Beauvillain de Montreuil C, Prevost B, Lefebvre J, et al. Post-surgical adjuvant chemotherapy in extracapsular spread invaded lymph node (N+R+) of epidermoid carcinoma of the head and neck: a randomized multicentric trial. *Second international conference on head and neck cancer. American Society of Head and Neck Surgery*1988;74.
- [126]. Laramore GE, Scott CB, al-Sarraf M, Haselow RE, Ervin TJ, Wheeler R, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. *International Journal of Radiation Oncology, Biology, Physics*1992;23:705–13.
- [127]. Yoshino K, Sato T, Nakai Y, Tanabe M, Matsunaga T, Kozuka T, et al. A comparative clinical study of adjuvant chemotherapy of tumors in the head and neck areas by means of HCFU. *Jap J Cancer Chemother*1991;18:2581–8.
- [128]. Rao RS, Parikh DM, Parikh HK, Bhansali MB, Deshmane VH, Fakh AR. Perioperative chemotherapy in patients with oral cancer. *Am J Surg*1994;168:262–7. [PubMed: 8080065]
- [129]. Kotani A, Sunada O, Tamura M, Takaku S, Kobayashi A, Asakura A, et al. Multiple cooperative study of UFT-adjuvant chemotherapy for malignant tumor in the jaw and oral cavities. *Jap J Cancer Chemother*1994;21:987–92.
- [130]. Tsukuda M, Ogasawara H, Kaneko S, Komiyama S, Horiuchi M, Inuyama Y, et al. A prospective randomized trial of adjuvant chemotherapy with UFT for head and neck carcinoma. *Jap J Cancer Chemother*1994;21:1169–77.
- [131]. Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial. *Lancet Oncol*2013;14:257–64. [PubMed: 23414589]
- [132]. Geoffrois L, Martin L, De Raucourt D, Sun XS, Tao Y, Maingon P, et al. Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: Results of the GORTEC 2007–02 Phase III Randomized Trial. *J Clin Oncol*2018;36:3077–83. 10.1200/JCO.2017.76.2591. [PubMed: 30016178]
- [133]. Stromberger C, Knecht R, Raguse JD, Keilholz U, Tribius S, Busch C-J, et al. Standard or split TPF induction chemotherapy followed by bioradiation: ICRAT randomized phase II study. *JCO*2016;34:6035–6035. 10.1200/JCO.2016.34.15_suppl.6035.
- [134]. Tousif D, Sarathy V, Kumar R, Naik R. Randomized Controlled Study Comparing Efficacy and Toxicity of Weekly vs. 3-Weekly Induction Chemotherapy in Locally Advanced Head and

Neck Squamous Cell Carcinoma. *Frontiers in Oncology*2020;10:1284. 10.3389/fonc.2020.01284. [PubMed: 32850394]

- [135]. Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. *Lancet Oncol*2015;16:645–55. 10.1016/S1470-2045(15)70126-9. [PubMed: 25957714]
- [136]. Fayard F, Petit C, Lacas B, Pignon JP. Impact of missing individual patient data on 18 meta-analyses of randomised trials in oncology: Gustave Roussy experience. *BMJ Open*2018;8. 10.1136/bmjopen-2017-020499.
- [137]. Zakeri K, Rotolo F, Lacas B, Vitzthum LK, Le Q-T, Gregoire V, et al. Predictive classifier for intensive treatment of head and neck cancer. *Cancer*2020;126:5263–73. 10.1002/cncr.33212. [PubMed: 33017867]




Fig. 1. Efficacy of loco-regional treatment plus chemotherapy versus loco-regional treatment alone by timing of chemotherapy. (A) Overall survival (see web-Figure 2, 10 and 11 for detailed HR plot), (B) Event-free survival. Dotted line and centre of the black diamond are the overall pooled hazard ratio. Horizontal tip of the diamond is the 95% confidence interval. Centre of the squares correspond are the HR of each chemotherapy timing. Area of the square is proportional to the number of deaths in each group of trials. CI: Confidence

Interval, CT: Chemotherapy, HR: Hazard Ratio, LRT: Loco-Regional Treatment, O-E: Observed minus Expected.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Fig. 2. Overall survival – Survival curves of loco-regional treatment plus chemotherapy and loco-regional treatment alone by timing. (A) Induction chemotherapy, (B) Concomitant chemotherapy, (C) Adjuvant chemotherapy. CI: confidence interval, CT: Chemotherapy, LRT: Loco-Regional Treatment.




Fig. 3. Subgroup analyses for loco-regional treatment plus chemotherapy versus loco-regional treatment alone. (A) By performance status for induction chemotherapy, (B) By age for concomitant chemotherapy. CI: Confidence Interval, CT: Chemotherapy, LRT: Loco-Regional Treatment, PS: Performance Status.

Table 1

Results of the addition of chemotherapy to loco-regional treatment.

	Overall survival	120-day mortality	Event-free survival	Cancer mortality %	Non-cancer mortality %	Loco-regional failure *	Distant failure *
Induction							
No. events/No. patients	4692/7054	470/7054	4556/6374	979/2031	320/2031	2574/6342	761/5582
HR of chemotherapy effect [95% CI]; <i>p</i> -value	0.96 [0.90; 1.01] <i>p</i> = 0.14	1.07 [0.89; 1.28] <i>p</i> = 0.47	0.96 [0.90; 1.02] <i>p</i> = 0.14	0.97 [0.86; 1.10] <i>p</i> = 0.67	0.84 [0.67; 1.05] <i>p</i> = 0.12	1.07 [0.99; 1.15] <i>p</i> = 0.09	0.76 [0.66; 0.88] <i>p</i> = 0.0002
Heterogeneity: <i>p</i> -value (<i>I</i> ²)	<i>p</i> = 0.63 (0%)	<i>p</i> = 0.46 (1%)	<i>p</i> = 0.25 (12%)	<i>p</i> = 0.24 (19%)	<i>p</i> = 0.28 (16%)	<i>p</i> < 0.0001 (63%)	<i>p</i> < 0.0001 (97%)
Absolute difference at 5 years [95% CI]	+2.2% [0.2; +4.6]	NA	+1.4% [0.9; +3.7]	0.7% [5.5; +4.1]	4.8% [0.4; +9.2]	+3.2% [+0.8; +5.7]	4.1% [6.0; +2.2]
Absolute difference at 10 years [95% CI]	+1.3% [1.9; +4.5]	NA	0.6% [3.6; +2.4]	NA	NA	+4.6% [+1.7; +7.5]	3.5% [5.7; 1.3]
Concomitant							
No. events/No. patients	7944/10,680	716/10,680	8345/10,457	3730/6483	955/6483	4766/10,076	1034/9022
HR of chemotherapy effect [95% CI]; <i>p</i> -value	0.83 [0.79; 0.86] <i>p</i> < 0.0001	1.07 [0.92; 1.24] <i>p</i> = 0.37	0.80 [0.77; 0.84] <i>p</i> < 0.0001	0.79 [0.74; 0.84] <i>p</i> < 0.0001	1.01 [0.89; 1.16] <i>p</i> = 0.83	0.71 [0.67; 0.75] <i>p</i> < 0.0001	1.04 [0.92; 1.18] <i>p</i> = 0.48
Heterogeneity: <i>p</i> -value (<i>I</i> ²)	<i>p</i> = 0.0002 (42%)	<i>p</i> = 0.01 (30%)	<i>p</i> = 0.04 (24%)	<i>p</i> = 0.18 (18%)	<i>p</i> = 0.80 (0%)	<i>p</i> < 0.0001 (85%)	<i>p</i> < 0.0001 (96%)
Absolute difference at 5 years [95% CI]	+6.5% [+4.6; +8.4]	NA	+5.8% [+4.1; +7.5]	9.8% [12.4; 7.2]	+2.9% [+0.1; +5.7]	9.3% [11.3; 7.3]	+0.2% [1.0; +1.6]
Absolute difference at 10 years [95% CI]	+3.6% [+1.8; +5.4]	NA	+3.1% [+1.5; +4.7]	NA	NA	9.6% [11.6; 7.5]	+0.2% [1.2; +1.6]
Adjuvant							
No. events/No. patients	1605/2915	127/2915	1461/2416	NA	NA	571/2416	324/2224
HR of chemotherapy effect [95% CI]; <i>p</i> -value	1.02 [0.92; 1.13] <i>p</i> = 0.69	1.89 [1.33; 2.68] <i>p</i> = 0.0003	0.98 [0.88; 1.09] <i>p</i> = 0.72	NA	NA	0.84 [0.72; 1.00] <i>p</i> = 0.04	0.77 [0.62; 0.96] <i>p</i> = 0.02
Heterogeneity: <i>p</i> -value (<i>I</i> ²)	<i>p</i> = 0.21 (23%)	<i>p</i> = 0.10 (34%)	<i>p</i> = 0.03 (47%)	NA	NA	<i>p</i> = 0.16 (29%)	<i>p</i> < 0.0001 (98%)
Absolute difference at 5 years [95% CI]	0.3% [4.3; +3.7]	NA	0.6% [5.0; +3.8]	NA	NA	3.7% [7.2; 0.2]	3.0% [6.0; 0.0]
Absolute difference at 10 years [95% CI]	+1.2% [4.1; +6.5]	NA	+3.6% [2.7; +9.9]	NA	NA	3.6% [7.2; 0.0]	3.2% [6.5; +0.2]
Interaction test (timing × treatment effect)	<i>p</i> < 0.0001	0.01	<i>p</i> < 0.0001	<i>p</i> = 0.003	<i>p</i> = 0.15	<i>p</i> < 0.0001	<i>p</i> = 0.001

CI: Confidence Interval, HR: Hazard Ratio, NA: Not Applicable.

Absolute differences at 5 and 10 years are absolute differences of survival for overall survival, and event-free survival, absolute differences of mortality for cancer mortality and non-cancer mortality, and absolute differences of cumulative incidence for loco-regional failure and distant failure.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

* HR are sub-HR estimated with Fine and Gray model.

% Data on cancer/non-cancer deaths were available for only two trials (5 comparisons) for the adjuvant timing.

All patients were analysed for OS. Six comparisons (1402 patients) were excluded from the analyses of EFS, LRF and DF due to incomplete data regarding failures [33,34,44,89,126]. One additional comparison (371 patients) was excluded from the analyses of LRF and DF because of missing failure location [82,83]. Concerning cancer and non-cancer mortality and induction timing, out of 25 recent comparisons (PF/TPF subsets: 3870 patients), 11 (1839 patients) were excluded because of lack of data ([29,30,59-63,68,69,71-74] and two unpublished trials: BNH003, EORTC 24844). For concomitant timing, out of 41 recent comparisons (first and second update: 6911 patients), four (428 patients) were excluded for the same reason [22,32,33].

See Web-Appendix 8 for the study of the source of heterogeneity.